Vertical hepatitis C virus transmission: Main questions and answers
- PMID: 25232447
- PMCID: PMC4163737
- DOI: 10.4254/wjh.v6.i8.538
Vertical hepatitis C virus transmission: Main questions and answers
Abstract
Hepatitis C virus (HCV) affects about 3% of the world's population and peaks in subjects aged over 40 years. Its prevalence in pregnant women is low (1%-2%) in most western countries but drastically increases in women in developing countries or with high risk behaviors for blood-transmitted infections. Here we review clinical, prognostic and therapeutic aspects of HCV infection in pregnant women and their offspring infected through vertical transmission. Pregnancy-related immune weakness does not seem to affect the course of acute hepatitis C but can affect the progression of chronic hepatitis C. In fact, postpartum immune restoration can exacerbate hepatic inflammation, thereby worsening the liver disease, particularly in patients with liver cirrhosis. HCV infection increases the risk of gestational diabetes in patients with excessive weight gain, premature rupture of membrane and caesarean delivery. Only 3%-5% of infants born to HCV-positive mothers have been infected by intrauterine or perinatal transmission. Maternal viral load, human immunodeficiency virus coinfection, prolonged rupture of membranes, fetal exposure to maternal infected blood consequent to vaginal or perineal lacerations and invasive monitoring of fetus increase the risk of viral transmission. Cesarean delivery and breastfeeding increases the transmission risk in HCV/human immunodeficiency virus coinfected women. The consensus is not to offer antiviral therapy to HCV-infected pregnant women because it is based on ribavirin (pregnancy category X) because of its embryocidal and teratogenic effects in animal species. In vertically infected children, chronic C hepatitis is often associated with minimal or mild liver disease and progression to liver cirrhosis and hepatocarcinoma is lower than in adults. Infected children may be treated after the second year of life, given the adverse effects of current antiviral agents.
Keywords: Antiviral therapy; Hepatitis C infection; Pregnancy; Prevention; Vertical transmission.
Similar articles
-
Hepatitis C in Pregnancy.Diseases. 2018 Apr 27;6(2):31. doi: 10.3390/diseases6020031. Diseases. 2018. PMID: 29702563 Free PMC article.
-
Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression.World J Gastroenterol. 2016 Jan 28;22(4):1382-92. doi: 10.3748/wjg.v22.i4.1382. World J Gastroenterol. 2016. PMID: 26819507 Free PMC article. Review.
-
#38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission.Am J Obstet Gynecol. 2016 Jan;214(1):6-14. doi: 10.1016/j.ajog.2015.09.100. Epub 2015 Oct 8. Am J Obstet Gynecol. 2016. PMID: 26454123 Review.
-
The management of HCV-infected pregnant women.Ann Hepatol. 2010;9 Suppl:92-7. Ann Hepatol. 2010. PMID: 20714003
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714 Review.
Cited by
-
Placental deficiency during maternal SARS-CoV-2 infection.Placenta. 2022 Jan;117:47-56. doi: 10.1016/j.placenta.2021.10.012. Epub 2021 Oct 23. Placenta. 2022. PMID: 34768168 Free PMC article.
-
SARS-CoV-2 Infection in Pregnant Women: Neuroimmune-Endocrine Changes at the Maternal-Fetal Interface.Neuroimmunomodulation. 2021;28(1):1-21. doi: 10.1159/000515556. Epub 2021 Apr 28. Neuroimmunomodulation. 2021. PMID: 33910207 Free PMC article. Review.
-
Placental Immune Responses to Viruses: Molecular and Histo-Pathologic Perspectives.Int J Mol Sci. 2021 Mar 13;22(6):2921. doi: 10.3390/ijms22062921. Int J Mol Sci. 2021. PMID: 33805739 Free PMC article. Review.
-
Perinatal transmission of hepatitis C virus: an update.Arch Med Sci. 2019 Mar 15;16(6):1360-1369. doi: 10.5114/aoms.2019.83644. eCollection 2020. Arch Med Sci. 2019. PMID: 33224335 Free PMC article.
-
Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV-2s.Prenat Diagn. 2020 Dec;40(13):1655-1670. doi: 10.1002/pd.5765. Epub 2020 Oct 4. Prenat Diagn. 2020. PMID: 32529643 Free PMC article. Review.
References
-
- Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
-
- Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567. - PubMed
-
- NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19:1–46. - PubMed
-
- Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714. - PubMed
-
- WHO. Global Alert and Response (GAR). Letter: Hepatitis C virus. Available from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources